Blog
RSS FeedPosted by Michael Wonder on 22 Apr 2016
NICE recommends Jevtana (cabazitaxel) for prostate cancer
22 April 2016 - NICE has issued final guidance recommending cabazitaxel (Jevtana, Sanofi) for some prostate cancer patients. This is a ...
Posted by Michael Wonder on 15 Apr 2016
NICE recommends ataluren for treating Duchenne muscular dystrophy caused by a nonsense mutation
15 April 2016 - NICE has today recommended ataluren (Translarna, PTC Therapeutics) for treating children aged 5 and over with Duchenne ...
Posted by Michael Wonder on 08 Apr 2016
NICE appraisal consultation for azacitidine (Vidaza) for patients with acute myeloid leukaemia
8 April 2016 - The Department of Health has asked NICE to produce guidance on the use of azacitidine in the ...
Posted by Michael Wonder on 08 Apr 2016
NICE appraisal consultation for mepolizumab (Nucala) for patients with severe eosinophilic asthma
4 April 2016 - The Department of Health has asked NICE to produce guidance on using mepolizumab in the NHS in ...
Posted by Michael Wonder on 04 Apr 2016
Roche seeks to avoid cancer drug drama with U.K. price talks
1 April 2016 - Roche Holding AG said it’s open to discussing ways to set prices for tumor-fighting treatments in the ...
Posted by Michael Wonder on 01 Apr 2016
NHS England funds Janssen's HIV pill Rezolsta
1 April 2016 - NHS England will release crucial funding for HIV therapy Rezolsta, its once-daily, fixed-dose combination of darunavir ethanolate ...
Posted by Michael Wonder on 31 Mar 2016
NICE tackles complex health issues for people with multimorbidity
31 March 2016 - NICE has issued draft guidance to help optimise care for people with 2 or more long-term health ...
Posted by Michael Wonder on 29 Mar 2016
NICE publishes report on approaches to assessing innovative regenerative medicines
29 March 2016 - NICE has today published a report describing a study exploring the assessment and appraisal of regenerative medicines ...
Posted by Michael Wonder on 27 Mar 2016
Welsh Government overrules NICE's rejection of Celgene's pancreatic cancer drug Abraxane
18 March 2016 - Patients with pancreatic cancer living in Wales will no doubt welcome news that Celgene’s Abraxane will continue ...
Posted by Michael Wonder on 23 Mar 2016
NICE consults on draft guidance for new cystic fibrosis treatment
23 March 2016 - NICE has issued draft guidance which does not recommend Orkambi (lumacaftor-ivacaftor marketed by Vertex Pharmaceuticals) for treating ...
Posted by Michael Wonder on 21 Mar 2016
NICE recommends abiraterone acetate for prostate cancer
21 March 2016 - NICE has issued final guidance recommending abiraterone (marketed as Zytiga by Janssen) for some prostate cancer patients*. ...
Posted by Michael Wonder on 21 Mar 2016
NICE confirms support for Novartis' heart drug Entresto
20 March 2016 - Cost regulators for the National Health Service in England and Wales have reiterated their support for the ...
Posted by Michael Wonder on 20 Mar 2016
Crossing the line: NICE’s value for money threshold
9 March 2016 - John Appleby explains the link between the NICE threshold and the NHS budget and considers whether it ...
Posted by Michael Wonder on 16 Mar 2016
NICE consults on ‘no’ recommendation for skin cancer drug talimogene laherparepvec
16 March 2016 - NICE has today issued draft guidance not recommending talimogene laherparepvec (Imlygic, Amgen) as an option for people ...
Posted by Michael Wonder on 08 Mar 2016
NICE to reject Humira for inflammatory skin disease
8 March 2016 - Cost regulators for the NHS in England and Wales are leaning towards a ‘no’ on the use ...